Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Tetrabuthylammonium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A1 | O15245 | 4/20 | 0.92 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.79 |
| ▸ | TSHR | P16473 | 2/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.69 |
| ▸ | TP53 | P04637 | 1/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.69 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.69 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.69 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.69 |
| ▸ | DNM1 | Q05193 | 6/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tetrabuthylammonium SCHEMBL25195464 | 1.00 | SLC22A1 (0.92) | SLC22A1SLC22A2TSHRALDH1A1TP53 | |
| Tetrabuthylammonium SCHEMBL987326 | 1.00 | SLC22A1 (0.92) | SLC22A1SLC22A2TSHRALDH1A1TP53 | |
| Tetrabuthylammonium SCHEMBL7960336 | 1.00 | SLC22A1 (0.92) | SLC22A1SLC22A2TSHRALDH1A1TP53 | |
| Tetrabuthylammonium SCHEMBL28480846 | 1.00 | SLC22A1 (0.92) | SLC22A1SLC22A2TSHRALDH1A1TP53 | |
| Tetrabuthylammonium SCHEMBL28633808 | 1.00 | SLC22A1 (0.92) | SLC22A1SLC22A2TSHRALDH1A1TP53 | |
| Tetrabuthylammonium SCHEMBL987325 | 0.96 | SLC22A1 (0.86) | SLC22A1SLC22A2TSHRALDH1A1TP53 | |
| Tetrabuthylammonium SCHEMBL29289305 | 0.96 | SLC22A1 (0.86) | SLC22A1SLC22A2TSHRALDH1A1TP53 | |
| Tetrabuthylammonium SCHEMBL21525928 | 0.96 | SLC22A1 (0.86) | SLC22A1SLC22A2TSHRALDH1A1TP53 | |
| Tetrabuthylammonium SCHEMBL22720005 | 0.96 | SLC22A1 (0.86) | SLC22A1SLC22A2TSHRALDH1A1TP53 | |
| Tetrabuthylammonium SCHEMBL28960737 | 0.96 | SLC22A1 (0.86) | SLC22A1SLC22A2TSHRALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4646629-A1 | LIQUID CRYSTALS SWITCHABLE STACK, LIQUID CRYSTALS MIXTURE, GLAZING UNIT AND BUILDING PRODUCT | Saint-Gobain Glass France (FR) | 2025-11-12 | — | — | EP | claimed |
| WO-2024146858-A1 | LIQUID CRYSTALS SWITCHABLE STACK, LIQUID CRYSTALS MIXTURE, GLAZING UNIT AND BUILDING PRODUCT | SAINT-GOBAIN GLASS FRANCE (FR) | 2024-07-11 | — | — | WO | claimed |
| EP-4398029-A1 | LIQUID CRYSTALS SWITCHABLE STACK, LIQUID CRYSTALS MIXTURE, AND SYSTEM WITH LIQUID CRYSTALS SWITCHABLE STACK | Saint-Gobain Glass France (FR) | 2024-07-10 | — | — | EP | claimed |
| US-4867790-A | DELAYED POLYMERIZATION, SULFONIUM INITIATOR | ESPE STIFTUNG & CO. PRODUKTIONS- UND VERTRIEBS KG (DE) | 1989-09-19 | — | — | US | claimed |
| WO-2026098529-A1 | KINESIN KIF18A INHIBITORS AND USE THEREOF | SHANGHAI APEIRON THERAPEUTICS COMPANY LIMITED (CN) | 2026-05-15 | — | — | WO | disclosed |
| EP-4673515-A1 | SILICON-BASED LIQUID CRYSTAL ALIGNMENT AGENT FOR SMART WINDOWS | Saint-Gobain Glass France (FR) | 2026-01-07 | — | — | EP | disclosed |
| EP-4646629-A1 | LIQUID CRYSTALS SWITCHABLE STACK, LIQUID CRYSTALS MIXTURE, GLAZING UNIT AND BUILDING PRODUCT | Saint-Gobain Glass France (FR) | 2025-11-12 | — | — | EP | disclosed |
| EP-3463362-B1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS GPR120 AGONISTS | MERCK SHARP & DOHME LLC (US) | 2025-09-03 | — | — | EP | disclosed |
| US-20250236623-A1 | PYRROLO[1,2-f][1,2,4]TRIAZINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2025-07-24 | — | — | US | disclosed |
| US-20240391873-A1 | PROCESS FOR THE PREPARATION OF PEGYLATED ADRENOMEDULLIN, ITS INTERMEDIATES AND USE THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2024-11-28 | — | — | US | disclosed |
| WO-2024180025-A1 | SILICON-BASED LIQUID CRYSTAL ALIGNMENT AGENT FOR SMART WINDOWS | SAINT-GOBAIN GLASS FRANCE (FR) | 2024-09-06 | — | — | WO | disclosed |
| EP-4424795-A1 | SILICON-BASED LIQUID CRYSTAL ALIGNMENT AGENT FOR SMART WINDOWS | Saint-Gobain Glass France (FR) | 2024-09-04 | — | — | EP | disclosed |
| US-6197963-B1 | TETRAHYDROPYRAN DERIVATIVES; PROTEIN G, SOMATOSTATIN, AND NATURAL KILLER CELL RECEPTOR ANTAGONISTS OR MIMETICS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2001-03-06 | — | — | US | disclosed |
| US-5922696-A | VIRICIDES AGAINST DNA VIRUSES, RETROVIRUSES AND VIRUSES INVOLVED IN TUMOR FORMATION, CYTOMEGALOVIRUS, VARICELLA-ZOSTER VIRUS, EPSTEIN-BARR VIRUS, HUMAN IMMUNODEFICIENCY VIRUSES | MERRELL PHARMACEUTICALS INC. (US) | 1999-07-13 | — | — | US | disclosed |
| US-5817647-A | VIRICIDES; ANTITUMOR AGENTS | MERRELL PHARMACEUTICALS INC. (US) | 1998-10-06 | — | — | US | disclosed |
| EP-0522956-B1 | Preparation of 2-(2-thienyl) ethylamine and synthesis of thieno [3,2-C] pyridine derivatives therefrom | SANOFI SA (FR) | 1997-02-05 | — | — | EP | disclosed |
| EP-0701562-A1 | UNSATURATED PHOSPHONATES DERIVATIVES OF PURINES AND PYRIMIDINES | MERRELL DOW PHARMA (US) | 1996-03-20 | — | — | EP | disclosed |
| WO-1994022882-A1 | UNSATURATED PHOSPHONATES DERIVATIVES OF PURINES AND PYRIMIDINES | MERRELL DOW PHARMACEUTICALS INC. (US) | 1994-10-13 | — | — | WO | disclosed |
| EP-0618214-A1 | Unsaturated phosphonate derivatives of purines and pyrimidines | MERRELL DOW PHARMACEUTICALS INC. (US) | 1994-10-05 | — | — | EP | disclosed |
| EP-0522956-A2 | Preparation of 2-(2-thienyl) ethylamine and synthesis of thieno [3,2-C] pyridine derivatives therefrom | SANOFI (FR) | 1993-01-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250236623-A1 | PYRROLO[1,2-f][1,2,4]TRIAZINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS | SYNJ1, SARS1, SYNJ2 | SLC22A1 1710/4885SLC22A2 2210/4885TSHR 2428/4885 |
| US-20240391873-A1 | PROCESS FOR THE PREPARATION OF PEGYLATED ADRENOMEDULLIN, ITS INTERMEDIATES AND USE THEREOF | ADM2, HAMP, SERPINC1 | SLC22A1 2094/4885SLC22A2 2590/4885TSHR 1180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.